STOCKS TELEGRAPH

Tag: NYSE: IGC

  • IGC Pharma, Inc. (IGC) Soars in After Market After Positive Alzheimer’s Research Results

    IGC Pharma, Inc. (NYSE: IGC) witnessed an unprecedented surge in its stock price following the release of encouraging phase 2 results in Alzheimer’s research. The initial uptick of 19.5% during trading hours was just the beginning of an exhilarating journey, as the afterhours session saw an additional 15% spike, propelling the stock beyond its 52-week high.

    Exploring IGC Pharma, Inc.

    Diving into IGC Pharma, Inc.’s niche reveals its commitment to pioneering cannabinoid-based alternative therapies. These innovative treatments target a range of conditions, including Alzheimer’s disease, Parkinson’s disease, and chronic pain.

    Leveraging the synergistic potential of cannabinoids like Tetrahydrocannabinol and Cannabidiol alongside complementary compounds forms the cornerstone of their research strategy, particularly in Alzheimer’s disease.

    Market Response and Anticipation

    The surge in trading volume, quadrupling average levels despite subdued market activity, underscores investors’ growing confidence in the company’s prospects. Speculation is rife that this bullish momentum may carry over into Thursday’s regular trading session, amplifying the excitement surrounding IGC Pharma, Inc.’s trajectory.

    Insights from Phase 2 Trial

    Significant attention is drawn to the recent interim results from the Phase 2 trial evaluating IGC-AD1’s potential in treating Agitation in dementia from Alzheimer’s Disease (AAD). These findings unveiled a tangible reduction in agitation levels compared to the placebo, hinting at a promising therapeutic avenue with IGC-AD1, thus highlighting the significance of this breakthrough.

    Understanding the Market

    Within the broader context, Alzheimer’s disease casts a long shadow, affecting millions of Americans. Of particular note is the often-overlooked Agitation in dementia from Alzheimer’s Disease (AAD), a condition exacerbating cognitive decline and burdening caregivers.

    Existing treatment modalities, fraught with risks, underscore the pressing need for safer and more efficacious alternatives, underscoring the potential significance of IGC-AD1.

    Conclusion

    In summary, the remarkable surge in IGC Pharma, Inc.’s stock price following positive phase 2 results underscores the growing recognition of cannabinoid-based therapies’ potential in addressing complex neurological conditions like AAD.

    As stakeholders await further developments, optimism pervades regarding the company’s trajectory and its ability to deliver treatment to patients in dire need.

  • What Is Driving The India Globalization (IGC) Stock Up In Premarket Session?

    India Globalization Capital Inc. (IGC) stock was up more than 2.6% in pre-market trading at $1.93 at the last check. Last session, IGC stock closed at $1.88, a decrease of -32.86% or -$0.92. During Friday’s session, India Globalization stock fluctuated between $1.86 and $2.38 per share. During the day, shares of the company’s stock exchanged hands in a volume of 23.35 million, exceeding its average daily volume of 9.28 million over the last 50 days and exceeding its YTD average volume of 6.07 million shares.

    IGC stock has gained 235.71% over the past 12 months, and it has gained 33.33% over the past week. India Globalization Capital has gained 21.29 percent over the last six months, and over the past three months, it has gained 17.50 percent. So far this year, IGC shares have returned 20.51%. As a result of news that a treatment patent has been issued, IGC stock is rising.

    In what field did India Globalization Capital have that patent?

    In order to treat conditions such as Alzheimer’s disease and pain, India Globalization Capital, Inc. (IGC) is developing cannabinoid-based therapies. Infrastructure and Life Sciences represent the company’s two main business lines. India Globalization Capital has its headquarters in Potomac, Maryland.

    On July 20, 2021, India Globalization announced that the United States Patent and Trademark Office (“USPTO”) had issued a patent (#11,065,225), announced the company last week.

    • The patent titled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease” was granted to IGC for the treatment of Alzheimer’s disease,
    • The original patent application was filed on August 1, 2016, by the University of South Florida (“USF”).
    • A license was entered into for the patent application and associated research on Alzheimer’s disease between IGC and USF on May 25, 2017.
    • As per the approved patent, India Globalization Capital’s proprietary formulation can be used to treat people who suffer from Alzheimer’s disease.
    • Phase 1 clinical trials for the company’s proprietary formulation, IGC-AD1, have already been announced.

    In its placebo-controlled Multiple Ascending Dose (MAD) phase 1 trial, India Globalization Capital recently announced that Cohort 3 of its IGC-AD1 using THC for patients suffering from Alzheimer’s disease was completed.

    Prospective uses for IGC’s product:

    To For the first time to the best of IGC’s knowledge, low doses of THC, which is a psychoactive member of the cannabinoid class of products produced by the Cannabis sativa plant, have been used to treat Alzheimer’s patients. India Globalization was motivated by the potential that if the proposed clinical trials for IGC-AD1 prove successful, the drug could offer some relief to the estimated 50 million people who are anticipated to be impacted by Alzheimer’s disease by 2030.